NO20052976L - Fosfodiesterase-4-inhibitorer. - Google Patents

Fosfodiesterase-4-inhibitorer.

Info

Publication number
NO20052976L
NO20052976L NO20052976A NO20052976A NO20052976L NO 20052976 L NO20052976 L NO 20052976L NO 20052976 A NO20052976 A NO 20052976A NO 20052976 A NO20052976 A NO 20052976A NO 20052976 L NO20052976 L NO 20052976L
Authority
NO
Norway
Prior art keywords
phosphodiesterase
inhibitors
compounds
formulas
iii
Prior art date
Application number
NO20052976A
Other languages
English (en)
Other versions
NO20052976D0 (no
Inventor
Richard A Schumacher
Ashok Tehim
Allen T Hopper
Elizabeth Doorly Graham
Original Assignee
Memory Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memory Pharm Corp filed Critical Memory Pharm Corp
Publication of NO20052976D0 publication Critical patent/NO20052976D0/no
Publication of NO20052976L publication Critical patent/NO20052976L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

PDE4-inhibering oppnås ved hjelp av nye nitroksidforbindelser, f.eks. N-substituerte anilin- og difenylamin-analoger. Forbindelsene ifølge den foreliggende oppfinnelse har formlene I-III: (I) (II) (III) hvor A, B, D, R1, R2, R3, R7, R8, R9, R10 og R6 er som definert her.
NO20052976A 2002-11-19 2005-06-17 Fosfodiesterase-4-inhibitorer. NO20052976L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42722102P 2002-11-19 2002-11-19
PCT/US2003/036986 WO2004046113A2 (en) 2002-11-19 2003-11-19 Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors

Publications (2)

Publication Number Publication Date
NO20052976D0 NO20052976D0 (no) 2005-06-17
NO20052976L true NO20052976L (no) 2005-08-18

Family

ID=32326501

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052976A NO20052976L (no) 2002-11-19 2005-06-17 Fosfodiesterase-4-inhibitorer.

Country Status (16)

Country Link
US (3) US7087625B2 (no)
EP (1) EP1569908B1 (no)
JP (1) JP2006508987A (no)
KR (1) KR20050075430A (no)
CN (1) CN100513397C (no)
AT (1) ATE481387T1 (no)
AU (1) AU2003295656B2 (no)
BR (1) BR0315705A (no)
CA (1) CA2506297A1 (no)
DE (1) DE60334243D1 (no)
MX (1) MXPA05005345A (no)
NO (1) NO20052976L (no)
NZ (1) NZ540138A (no)
RU (1) RU2356893C2 (no)
WO (1) WO2004046113A2 (no)
ZA (1) ZA200503995B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7153871B2 (en) * 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US20030149052A1 (en) * 2002-01-22 2003-08-07 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
HRP20050082A2 (en) * 2002-07-19 2005-06-30 Memory Pharmaceuticals Corporation 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
AU2003256616B2 (en) * 2002-07-19 2009-08-27 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
CA2500727A1 (en) * 2002-10-03 2004-04-15 Targegen, Inc. Vasculostatic agents and methods of use thereof
ES2211344B1 (es) * 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
US20090048255A1 (en) * 2003-07-21 2009-02-19 Schumacher Richard A Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
EP2543376A1 (en) 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazine inhibitors of kinases
ES2251866B1 (es) * 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) * 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
AU2005276974B2 (en) 2004-08-25 2012-08-02 Targegen, Inc. Heterocyclic compounds and methods of use
WO2006135828A2 (en) * 2005-06-10 2006-12-21 Memory Pharmaceuticals Corporation Trisubstituted amines as phosphodiesterase 4 inhibitors
US8389538B2 (en) * 2007-02-27 2013-03-05 National University Corporation Okayama University Rexinoid compound having alkoxy group
ES2320954B1 (es) * 2007-03-02 2010-03-16 Laboratorio Almirall S.A. Nuevo procedimiento de preparacion de 3-metil-4-fenilisoxazolo (3,4-d)iridazin-7(6h)-ona.
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
MX2009010946A (es) * 2007-04-11 2009-10-29 Alcon Res Ltd Uso de un inhibidor del factor de necrosis tumoral alfa mas una antihistamina para tratar rinitis alergica y conjuntivitis alergica.
WO2009067607A2 (en) * 2007-11-20 2009-05-28 Memory Pharmaceuticals Corporation Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders
EP2070913A1 (en) 2007-12-14 2009-06-17 CHIESI FARMACEUTICI S.p.A. Ester derivatives as phosphodiesterase inhibitors
EP2110375A1 (en) * 2008-04-14 2009-10-21 CHIESI FARMACEUTICI S.p.A. Phosphodiesterase-4 inhibitors belonging to the tertiary amine class
US20100029689A1 (en) * 2008-07-02 2010-02-04 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
WO2010041449A1 (ja) * 2008-10-09 2010-04-15 国立大学法人 岡山大学 Rxr作動性物質を有効成分とする抗アレルギー剤
KR20120091037A (ko) * 2009-10-01 2012-08-17 알콘 리서치, 리미티드 올로파타딘 조성물 및 그의 용도
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
CN108299400B (zh) 2013-03-14 2021-02-19 达特神经科学(开曼)有限公司 作为pde4抑制剂的取代的吡啶和取代的吡嗪化合物

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698711A (en) 1991-01-28 1997-12-16 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
GB9311281D0 (en) 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd Novel composition of matter
US5935978A (en) 1991-01-28 1999-08-10 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
US6096768A (en) 1992-01-28 2000-08-01 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
ES2102036T3 (es) 1992-06-15 1997-07-16 Celltech Therapeutics Ltd Derivados con grupo fenilo trisustituido utilizados como inhibidores selectivos de la fosfodiesterasa iv.
EP0652868B1 (en) 1992-07-28 2004-11-10 Aventis Pharma Limited INHIBITORS OF c-AMP PHOSPHODIESTERASE
US5679696A (en) 1992-07-28 1997-10-21 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group
US5814651A (en) 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
US5622977A (en) 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
TW263495B (no) 1992-12-23 1995-11-21 Celltech Ltd
RU2083562C1 (ru) * 1993-02-05 1997-07-10 Исихара Сангио Кайся Лтд. Производные пиридина, способ их получения, инсектицидная композиция
GB9304919D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304920D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
WO1994027971A1 (en) 1993-05-27 1994-12-08 Smithkline Beecham Laboratoires Pharmaceutiques Anti-arrhythmic n-substituted 3-benzazepines or isoquinolines
CN1046939C (zh) 1993-07-02 1999-12-01 比克·古尔顿·劳姆贝尔格化学公司 氟烷氧基取代的苯甲酰胺类及其制备方法和应用
GB9315595D0 (en) 1993-07-28 1993-09-08 Res Inst Medicine Chem New compounds
ATE260911T1 (de) 1993-12-22 2004-03-15 Celltech R&D Ltd Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe
GB9326600D0 (en) 1993-12-22 1994-03-02 Celltech Ltd Chemical compounds
GB9401460D0 (en) * 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US5786354A (en) 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
GB9412571D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412573D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
FR2729142A1 (fr) 1995-01-06 1996-07-12 Smithkline Beecham Lab Nouvelles amines heterocycliques, leur procede de preparation et leur utilisation en tant que medicaments et notamment en tant qu'agents anti-arythmiques
US5731477A (en) 1995-01-31 1998-03-24 Smithkline Beecham Corporation Method for synthesis of aryl difluoromethyl ethers
WO1996036611A1 (en) 1995-05-19 1996-11-21 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
IT1275433B (it) 1995-05-19 1997-08-07 Smithkline Beecham Farma Derivati di diarildiammine
FR2735777B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
GB9603723D0 (en) 1996-02-22 1996-04-24 Merck & Co Inc Diphenyl pyridyl derivatives as pde iv inhibitors
US5710170A (en) 1995-12-15 1998-01-20 Merck Frosst Canada, Inc. Tri-aryl ethane derivatives as PDE IV inhibitors
EP0873311A1 (en) * 1995-12-15 1998-10-28 Merck Frosst Canada Inc. Tri-aryl ethane derivatives as pde iv inhibitors
GB9526243D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
WO1997048697A1 (en) * 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
EP0912558B1 (en) 1996-06-25 2003-07-09 Pfizer Inc. Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors
JPH1072415A (ja) 1996-06-26 1998-03-17 Nikken Chem Co Ltd ３−アニリノ−２−シクロアルケノン誘導体
CA2264798A1 (en) 1996-09-04 1998-03-12 Pfizer Inc. Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
GB9625184D0 (en) 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
WO1998058901A1 (en) 1997-06-24 1998-12-30 Nikken Chemicals Co., Ltd. 3-anilino-2-cycloalkenone derivates
TW374919B (en) * 1997-08-28 1999-11-21 Hitachi Ltd Synchronous memory unit
US5919937A (en) 1997-10-29 1999-07-06 Merck & Co., Inc. Process for phosphodiesterase IV inhibitors
BR9812527A (pt) 1997-11-25 2000-07-25 Warner Lambert Co Inibidores de benzenossulfonamida de pde-iv e seu uso terapêutico
JP4754068B2 (ja) 1997-12-24 2011-08-24 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド δ−オピオイドレセプターに結合する４−［アリール（ピペリジン−４−イル）］アミノベンズアミド類
JP3542482B2 (ja) 1997-12-25 2004-07-14 日研化学株式会社 ３−アニリノ−２−シクロアルケノン誘導体
WO1999040085A1 (en) * 1998-02-09 1999-08-12 Darwin Discovery Limited Benzofuran-4-carboxamides and their therapeutic use
AU764005B2 (en) * 1999-02-25 2003-08-07 Merck Frosst Canada & Co. PDE IV inhibiting compounds, compositions and methods of treatment
US6180650B1 (en) 1999-04-23 2001-01-30 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
US6200993B1 (en) 1999-05-05 2001-03-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE4 inhibitors
GB2350110A (en) 1999-05-17 2000-11-22 Bayer Ag Pharmaceutically active benzofurans
ES2258459T3 (es) 1999-05-21 2006-09-01 Bristol-Myers Squibb Company Pirrolotriazinas inhibidoras de quinasas.
JP4434362B2 (ja) 1999-06-28 2010-03-17 興和創薬株式会社 ホスホジエステラーゼ阻害剤
EP1116711B1 (de) 1999-12-18 2005-12-14 Wella Aktiengesellschaft 2-Aminoalkyl-1,4-diaminobenzol-Derivate und diese Verbindungen enthaltende Färbemittel
MY123585A (en) * 2000-03-23 2006-05-31 Merck Canada Inc Tri-aryl-substituted-ethane pde4 inhibitors.
AU2001261962B2 (en) * 2000-05-25 2005-04-21 Merck Frosst Canada Ltd Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
ATE430742T1 (de) 2000-12-21 2009-05-15 Smithkline Beecham Corp Pyrimidinamine als angiogenesemodulatoren
US6699890B2 (en) 2000-12-22 2004-03-02 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
CN100378075C (zh) * 2001-01-22 2008-04-02 记忆药物公司 用作磷酸二酯酶4抑制剂的苯胺衍生物
AU2003256616B2 (en) * 2002-07-19 2009-08-27 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs

Also Published As

Publication number Publication date
EP1569908B1 (en) 2010-09-15
JP2006508987A (ja) 2006-03-16
MXPA05005345A (es) 2005-08-26
WO2004046113A3 (en) 2005-03-24
BR0315705A (pt) 2005-09-06
ZA200503995B (en) 2006-08-30
NZ540138A (en) 2008-07-31
RU2356893C2 (ru) 2009-05-27
DE60334243D1 (de) 2010-10-28
RU2005119627A (ru) 2006-01-27
ATE481387T1 (de) 2010-10-15
AU2003295656A2 (en) 2005-06-30
NO20052976D0 (no) 2005-06-17
WO2004046113A2 (en) 2004-06-03
US7700631B2 (en) 2010-04-20
AU2003295656B2 (en) 2010-11-11
EP1569908A2 (en) 2005-09-07
CA2506297A1 (en) 2004-06-03
KR20050075430A (ko) 2005-07-20
AU2003295656A1 (en) 2004-06-15
US7087625B2 (en) 2006-08-08
US20100173942A1 (en) 2010-07-08
CN100513397C (zh) 2009-07-15
US20060211865A1 (en) 2006-09-21
US20040152902A1 (en) 2004-08-05
CN1714081A (zh) 2005-12-28

Similar Documents

Publication Publication Date Title
NO20052976L (no) Fosfodiesterase-4-inhibitorer.
TW200602322A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
YU57603A (sh) Inhibitori fosfodiesteraze 4
NO20050870L (no) Fosfodiesterase 4-inhibitorer, inkludert N-substituerte anilin- og difenylaminanaloger
ATE449099T1 (de) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
HUP0402376A2 (hu) Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények
NO20070606L (no) Inhibitorer av IAP
TNSN03045A1 (en) QUINAZOLINES AS MMP-13 INHIBITORS
ES2193839B1 (es) Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
ATE338461T1 (de) Pyrazolpyrimidinfungizide
ATE389638T1 (de) Aminobenzamidderivate als inhibitoren der glycogensynthasekinase-3-
ATE491703T1 (de) Phthalazinonderivate
ATE444065T1 (de) 4(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidon-deriva e als pde-4-hemmer zur behandlung von neurologischen syndromen
CY1106132T1 (el) Παραγωγα πιπepιδινης ως αναστολεις καναλιου καλιου
PT1742642E (pt) Análogos de fosfonato de compostos inibidores da integrase do hiv
WO2010003084A3 (en) Phosphodiesterase 4 inhibitors
AR042362A1 (es) Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen
DE60325984D1 (de) 4-aminobenzofuranverbindungen als phosphodiesterase-4-inhibitoren
DE60314381D1 (de) Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
TNSN05277A1 (en) Novel bioisosteres of actinonin
EA200600608A1 (ru) Производные имидазопиридина как ингибиторы индуцируемой no-синтазы
NO20062152L (no) Fremstilling av 3-azabicyklo [3.1.0.]heksanderivater
ATE374751T1 (de) 3,4-dihydro-1h-chinolin-2-onderivate als norepinephrin-wiederaufnahme-hemmern
NO20050764L (no) Forbindelser